Nat Commun: Protein Analysis of Cellular Exosomes (EVs): Potential Monitoring Indicators for Treatment Response of Patients with Metastatic Breast Cancer

Metastatic breast cancer (MBC) is a heterogeneous disease including many different subtypes, and it is one of the leading causes of cancer deaths in women worldwide.
Although the current diagnosis and treatment ofthe diseaseare improving, there are still 25-28% of breast cancer (BC) patients diagnosed with MBC, and the 5-year survival rate of these patients is only 27%.

Metastatic breast cancer (MBC) is a heterogeneous disease including many different subtypes, and it is one of the leading causes of cancer deaths in women worldwide.
Metastatic breast cancer (MBC) is a heterogeneous disease including many different subtypes, and it is one of the leading causes of cancer deaths in women worldwide.
Breast cancer diagnosis

In MBC patients, real-time monitoring and prediction of treatment response is essential for the best personalized treatment plan.
Although tissue biopsy has been used to diagnose MBC, its invasiveness brings risks and increases morbidity, and there is not enough tissue available for detection as the disease progresses.

Although tissue biopsy has been used to diagnose MBC, its invasiveness brings risks and increases morbidity, and there is not enough tissue available for detection as the disease progresses.
Although tissue biopsy has been used to diagnose MBC, its invasiveness brings risks and increases morbidity, and there is not enough tissue available for detection as the disease progresses.

Due to the low sensitivity of computed tomography (CT) in monitoring treatment response, it cannot be used to predict disease progression.
Therefore, there is an urgent need for reliable, non-invasive tools to diagnose and monitor MBC.

Molecular profiling of circulating exosomes (EVs) provides a promising non-invasive means to diagnose, monitor and predict the occurrence and development of MBC.

However, the analysis of EV protein markers is easily confused by the presence of soluble protein counterparts in peripheral blood.

Thermophoresis aptamer sensor (TAS) for detecting EV protein markers

Thermophoresis aptamer sensor (TAS) for detecting EV protein markers

In this study, the researchers used a fast, sensitive, and low-cost thermophoretic aptamer sensor (TAS) to analyze the cancer-related protein profile of plasma EVs without interference from soluble proteins.
The results showed that EV markers (the weighted sum of eight EV protein markers) have high accuracy (91.
1%) for the discrimination of MBC, non-metastatic breast cancer (NMBC) and healthy blood donors (HD).

The researchers used a fast, sensitive, and low-cost thermophoretic aptamer sensor (TAS) to analyze the cancer-related protein profile of plasma EVs without interference from soluble proteins.
The researchers used a fast, sensitive, and low-cost thermophoretic aptamer sensor (TAS) to analyze the cancer-related protein profile of plasma EVs without interference from soluble proteins.

For MBC patients undergoing treatment, EV markers can accurately monitor the patient's response to treatment in training, validation, and prospective cohorts, and can be used as an independent prognostic factor for the progression-free survival of MBC patients.

Analysis of EV proteins in MBC, NMBC and HD by TAS

Analysis of EV proteins in MBC, NMBC and HD by TAS

All in all, the results of this study highlight the potential clinical utility of EVs in MBC monitoring.

The results of this study highlight the potential clinical utility of EVs in MBC monitoring.
The results of this study highlight the potential clinical utility of EVs in MBC monitoring.

Original source:

Tian, ​​F.

, Zhang, S.
, Liu, C.

org/10.

Leave a message here